Cynata Therapeutics (CYP) AGM 2024 presentation summary

Corporate overview and financials

• Share price as of 15 November 2024 was A$0.245, with a market capitalization of approximately A$44 million and cash reserves of about A$4.3 million.

• Largest shareholders include BioScience Managers (13.1%), Fidelity International (10.0%), and Fujifilm (4.5%), with the top 20 shareholders holding 47% of shares.

Clinical pipeline and progress

• Multiple clinical trials advanced in FY2024, including completion of patient enrolment for Phase 3 osteoarthritis and Phase 1 diabetic foot ulcer trials.

• Phase 2 aGvHD trial enrolled its first patient, and a Phase 1/2 kidney transplant trial was approved and commenced enrolment.

• Promising efficacy data: 87.6% median wound reduction in DFU trial and 60% two-year survival in steroid-resistant aGvHD.

Platform technology and manufacturing

• Cymerus™ platform uses a single donor iPSC bank to produce MSCs, ensuring batch-to-batch consistency, scalability, and retained potency.

• Overcomes traditional MSC manufacturing challenges such as donor variability, inconsistent potency, and scalability issues.

• Cymerus™ MSCs have a strong safety profile and can be used across multiple indications.